A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy (Q35180490)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

11 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

0 references

A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy (English)

1 reference

Europe PubMed Central

7 August 2017

diabetic retinopathy

10 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

monoclonal antibody

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

based on heuristic

inferred from title

postoperative complications

1 reference

3 September 2020

angiogenesis inhibitor

1 reference

5 November 2020

surgical blood loss

1 reference

18 July 2021

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Li-Quan Zhao

1

1 reference

Europe PubMed Central

7 August 2017

Huang Zhu

2

1 reference

Europe PubMed Central

7 August 2017

Pei-Quan Zhao

3

1 reference

Europe PubMed Central

7 August 2017

Yi-Qian Hu

4

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

27 January 2011

1 reference

Europe PubMed Central

7 August 2017

1 September 2011

11 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

British Journal of Ophthalmology

12 references

Europe PubMed Central

7 August 2017

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

95

1 reference

Europe PubMed Central

7 August 2017

1216-1222

1 reference

Europe PubMed Central

7 August 2017

9

1 reference

Europe PubMed Central

7 August 2017

copyright license

Creative Commons Attribution-NonCommercial

11 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

3 September 2020

5 November 2020

18 July 2021

on focus list of Wikimedia project

0 references

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Bevacizumab (Avastin) for the treatment of ocular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

13 July 2018

Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Overcoming the limitations of current meta-analysis of randomised controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161500

27 September 2018

Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21278146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21278146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21278146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJO.2010.189514

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35180490&oldid=1984295854"